KKR and ResMed Push the Focus-and-Platform Playbook Forward
Medtech leaders are narrowing portfolios and buying platform assets that strengthen core device franchises, improve capital deployment, and create consolidation leverage.
Updated
What is this trend?
Large medtech companies are sharpening portfolios around core device franchises while using divestitures and acquisitions to build scaled platforms with stronger recurring revenue and consolidation power.
- Divest non-core assets to fund debt paydown, buybacks, and sharper category focus.
- Buy scaled platforms, not just products, when they add manufacturing depth and acquisition capacity.
- Adjacency now needs a clear link to devices, recurring revenue, or strategic control.
- Software and services assets face a higher bar unless they reinforce the core franchise.
- Value is concentrating in assets that can anchor consolidation or deepen defensible device positions.
What’s the latest?
KKR’s $5.7 billion agreement to acquire Integer Holdings and ResMed’s divestiture of MatrixCare extend the focus-and-platform playbook that has been building over the past two weeks.
How it developed
- Integrated robotics, portfolio separations, governed device data, and QMSR compliance become competitive moats
- Portfolio Narrowing Drives Value-Creation Separations
- Robotic Surgery Scales, Workflow Control Tightens, and Regional Manufacturing Becomes a Moat
- Strategic Portfolio Consolidation
- Copay Relief Boosts Premium Biliary Endoscopy, and Simplification Fuels Cash Deployment
- Teleflex, Solventum, and Health Catalyst Turn Simplification Into Cash Deployment
Go deeper
Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.
